Main

processing priority

4

site type

0 (generic, awaiting analysis)

review version

11

html import

20 (imported)

Events

first seen date

2024-03-19 16:20:49

expired found date

-

created at

2024-06-07 07:05:52

updated at

2025-12-30 12:04:44

Domain name statistics

length

13

crc

27673

tld

2211

nm parts

0

nm random digits

0

nm rare letters

0

Connections

is subdomain of id

-

previous id

0

replaced with id

0

related id

-

dns primary id

31873516

dns alternative id

368217672

lifecycle status

0 (unclassified, or currently active)

Subdomains and pages

deleted subdomains

0

page imported products

0

page imported random

0

page imported parking

0

Error counters

count skipped due to recent timeouts on the same server IP

0

count content received but rejected due to 11-799

0

count dns errors

0

count cert errors

0

count timeouts

0

count http 429

0

count http 404

0

count http 403

0

count http 5xx

0

next operation date

-

Server

server bits

server ip

-

Mainpage statistics

mp import status

20

mp rejected date

-

mp saved date

-

mp size orig

74966

mp size raw text

4701

mp inner links count

1

mp inner links status

20 (imported)

Open Graph

title

AKEEGA™ (niraparib/abiraterone acetate) HCP

description

AKEEGA™, the first and only dual action tablet combining PARB inhibition and novel hormonal therapy for your adult patients. See full Safety & Prescribing Information.

site name

author

updated

2025-12-18 11:41:58

raw text

AKEEGA™ (niraparib/abiraterone acetate) Healthcare Professional Website For Healthcare Professionals Patient Website  Important Safety Information Medical Inquiries Prescribing Information  Stay Informed  For Heathcare Professionals BRCA m in Prostate Cancer Efficacy Safety & Tolerability Dosing Access & Support Find a Janssen Specialist Patient Website   Important Safety Information  Medical Inquiries   Prescribing Information  Stay Informed  Find a Janssen Specialist  IT'S A CLEAR TREATMENT PATH WITH AKEEGA™, IT'S A CLEAR TREATMENT PATH WITH AKEEGA™, THE ONLY FDA-APPROVED DUAL ACTION TABLET FOR BRCA + mCRPC AKEEGA™ is the first-and-only FDA-approved dual action tablet combining PARP inhibition and novel hormonal therapy to provide precision medicine for patients with BRCA + mCRPC. 1 Niraparib and abiraterone acetate (AKEEGA™) is a recommended treatment option by the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ® ) for...

Text analysis

redirect type

0 (-)

block type

0 (no issues)

detected language

1 (English)

category id

Nowotwory (78)

index version

2025110801

spam phrases

3

Text statistics

text nonlatin

0

text cyrillic

0

text characters

3669

text words

671

text unique words

309

text lines

120

text sentences

26

text paragraphs

7

text words per sentence

25

text matched phrases

9

text matched dictionaries

3

RSS

rss path

rss status

3 (priority 3 already searched, no matches found)

rss found date

-

rss size orig

0

rss items

0

rss spam phrases

0

rss detected language

0 (awaiting analysis)

inbefore feed id

-

inbefore status

0 (new)

Sitemap

sitemap status

30 (processing completed, results pushed to table crawler_sitemaps.ext_domain_sitemap_lists)

sitemap review version

1

sitemap urls count

11

sitemap urls adult

0

sitemap filtered products

0

sitemap filtered videos

0

sitemap found date

2024-03-24 16:08:04

sitemap process date

2024-11-08 05:14:22

sitemap first import date

-

sitemap last import date

-